换一批
换一批Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
第一作者：
Geoffrey I,Shapiro
第一单位：
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA. geoffrey_shapiro@dfci.harvard.edu
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);顺铂(Cisplatin);疾病恶化(Disease Progression);女(雌)性(Female);G2期(G2 Phase);基因, cdc(Genes, cdc);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤(Neoplasms);肽碎片(Peptide Fragments);cdc25磷酸酶类(cdc25 Phosphatases)
DOI
10.1158/1078-0432.CCR-10-2345
PMID
21220472
发布时间
2013-11-21
- 浏览200
Clinical cancer research
3431-42页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
